Company / Capital Expenditures
Anixa Biosciences Inc Capital Expenditures History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$15.8K
FY2022
5-year range
$15.8K / $175.5K
FY2018-FY2022
Trend
-91.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 7 years, ranging from $6,684 in FY2015 to $175,457 in FY2020.
Based on SEC 10-K filings.
$15,791 in FY2022 with a 5-year CAGR of -36.0%.
Declined from $38,404 to $15,791 over the past 3 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -25.6%
- 5-Year CAGR
- -36.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -36.0%, indicating a declining trend.
- In FY2022, capital expenditures decreased 91.0% year-over-year.
- Peak capital expenditures was recorded in FY2020.
- Lowest capital expenditures in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $15.8K | -91.0% |
| FY2020 | $175.5K | +356.9% |
| FY2019 | $38.4K | +27.2% |
| FY2018 | $30.2K | -79.4% |
| FY2017 | $146.5K | +167.5% |
| FY2016 | $54.8K | +719.5% |
| FY2015 | $6.7K | - |
| FY2014 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026